Company: ZLAB
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001628280-25-020478
Chunk: 51

Company: Zai Lab Ltd
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 51
---
, the Compensation Committee, with support from our independent compensation consultant, conducted an in-depth analysis to determine the appropriate peer group to evaluate 2024 compensation decisions in the context of the Company’s business strategy and operating parameters. The purpose of the peer group analysis was to enable the Company to use the appropriate comparator group and third-party data sources for our annual assessment of executive compensation. Following this analysis, the Compensation Committee determined that our peer group should be updated to reflect the Company’s current size and scope of our business. For example, we expanded our peer group and added certain companies that were deemed comparable in size and business scope (these new companies denoted with two asterisks in the table below), and we removed certain companies that were no longer deemed comparable in size or that had been acquired.

The peer group used to evaluate 2024 executive compensation decisions consisted of the following 20 companies*:

| ACADIA Pharmaceuticals, Inc.      |     | Insmed Incorporated            |
| Agios Pharmaceuticals, Inc.       |     | Ionis Pharmaceuticals, Inc.**  |
| Alkermes plc**                    |     | Mirati Therapeutics, Inc.      |
| Amicus Therapeutics, Inc.         |     | Neurocrine Biosciences, Inc.   |
| Apellis Pharmaceuticals, Inc.     |     | PTC Therapeutics, Inc.         |
| BeiGene, Ltd.                     |     | Sarepta Therapeutics, Inc.     |
| BioCryst Pharmaceuticals, Inc.    |     | Travere Therapeutics, Inc.**   |
| Blueprint Medicines Corporation   |     | Ultragenyx Pharmaceutical Inc. |
| Deciphera Pharmaceuticals, Inc.** |     | Vir Biotechnology, Inc.        |
| Exelixis, Inc.                    |     | Xencor, Inc.**                 |

*Removals from the peer group in 2024 include Alnylam Pharmaceuticals, Inc., argenx SE, CanSino Biologics, Inc., Innovent Biologics, Inc., and Shanghai Junshi Biosciences Co., Ltd.

** Represents new peer group members in 2024. Deciphera Pharmaceuticals, Inc. was acquired in June 2024 by Ono Pharmaceutical Co., Ltd.

For each of the companies in our peer group, we analyzed available data to identify comparable executive officers. We then compiled and analyzed the data for each comparable position. Our competitive analysis included the structure and design of the executive compensation programs as well